We think you are in Victoria. If not please click 'Change'

In your state, you are required to confirm you wish to access this information. Please enter 'QLD' or 'WA' in the field below to continue.

No thanks

Blood thinner to face action over fatal bleeding

Older couple on the coast | Shine Lawyers

A new blood thinning agent, marketed for having minimal side effects, may face litigation in the U.S. involving claims the medication has been linked to potentially fatal bleeding complications. Eliquis (Apixaban) is an anti-clotting agent used for persons with a heart irregularity known as atrial fibrillation to reduce risk of stroke. It is also used after knee or hip surgery with the aim of preventing deep vein thrombosis.

The proposed lawsuits indicate that although the side effects are similar to that of older blood thinning medications, Eliquis does not have a reversal agent to counteract severe bleeding events like its predecessors. Lawyers investigating this matter thus allege that drug companies Pfizer and Bristol-Myers manufactured Eliquis negligently and failed to warn consumers of risks associated with the medication.

Shortly after its release in Australia, Eliquis was included in a safety alert from the Therapeutic Goods Administration (TGA) on the 24th of September, 2014. The TGA reported that post market experience with these drugs revealed serious and potentially fatal bleeding complications.

The use of Eliquis may be increased due to its listing as a subsidised medicine under the Pharmaceutical Benefits Scheme. Furthermore, the drugs’ marketing promotes that it requires no dosage adjustments and involves minimal dietary regulation.

The claims against Eliquis have been criticised by experts who assert that injury could have been avoided if patients had undergone frequent visits with their healthcare practitioners. This poses a timely reminder that persons prescribed Eliquis should frequently visit their doctor for potential dose adjustment and become informed of the indications of bleeding complications and the need to seek urgent medical attention if bleeding is suspected.

If complications are experienced, Eliquis users should be encouraged to report these problems to the Therapeutic Goods Administration.

 

Click to read more about Xarelto, another blood thinner linked to fatal bleeding

Click to read about Product Liability claims

Written by Shine Lawyers on . Last modified: September 21, 2017.

Join the discussion

Share this article:

  • Agnes Adorjan wrote:

    My husband had a stroke a week ago, 6th March 2018, due to this medication. Luckily he survived, he is in hospital for weeks to come and he is possibly facing further side effects.
    If there is a class action against the manufacturers, I would like to join it.

    • Shine Lawyers wrote:

      Hi Agnes, I’m sorry to hear about your husband. At current we’re not investigating a class action relating to this medication but that doesn’t mean we might not be able to help your husband on an individual basis. If you’d like to get in touch with our New Client Team to provide more details they will be able to talk you through our services and let you know if we’re able to assist. You can find our contact details here: http://bit.ly/Shine-contact ~Steph.

  • Laura Smith wrote:

    My mother went on Elequis for 1 yr & has been off the drug for about 3 yrs but has suffered terrible side effects which she is still suffering, and the side affects are getting worse.

  • Faulty High-tech braking systems: Subaru and Honda Recalls

    The safety of cars with automatic braking systems have been called into question with car manufactures issuing worldwide recalls in response to faulty program software. Car manufactures Subaru and Honda have announced large recalls due to malfunctioning technology designed to prevent rear-end crashes and avoid hitting pedestrians, yet instead are putting the vehicles at risk […]

    Read more

    China-Australia Free Trade Agreement: potential commercial implications

    The China-Australia Free Trade Agreement (ChAFTA) was signed on the 17th June 2015, implementing a foundation in the next phase of inter-economic relationships between Australia and China. The potential for the ChAFTA to create opportunities for Australia is evident, with China accounting for Australia’s largest export market for goods and services and a nearly a […]

    Read more

    Breast implant suspended from Australian market

    The Therapeutic Goods Association (TGA) has imposed a 6 month suspension on Cereform silicone gel-filled breast implants and associated sizers from the Australian Register of Therapeutic Goods. Since 2009, about 4800 of the implants were sold in Australia. The action taken by the TGA will now prevent the devices from being supplied to the Australian […]

    Read more